[go: up one dir, main page]

PE20120331A1 - Agentes medicinales unidos a dipeptido - Google Patents

Agentes medicinales unidos a dipeptido

Info

Publication number
PE20120331A1
PE20120331A1 PE2011001237A PE2011001237A PE20120331A1 PE 20120331 A1 PE20120331 A1 PE 20120331A1 PE 2011001237 A PE2011001237 A PE 2011001237A PE 2011001237 A PE2011001237 A PE 2011001237A PE 20120331 A1 PE20120331 A1 PE 20120331A1
Authority
PE
Peru
Prior art keywords
alkyl
group
dipeptide
medicinal agent
breaking
Prior art date
Application number
PE2011001237A
Other languages
English (en)
Inventor
Richard D Dimarchi
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of PE20120331A1 publication Critical patent/PE20120331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPLEJO QUE COMPRENDE: (I) UN GRUPO DIPEPTIDO DE AUTO ROTURA NO ENZIMATICA DE ESTRUCTURA GENERAL (A-B) DONDE: A ES UN AMINOACIDO O HIDROXIL ACIDO; B ES UN AMINOACIDO N-ALQUILADO; (II) UN AGENTE MEDICINAL (Q) TAL COMO UN PEPTIDO BIOACTIVO QUE ESTA UNIDO COVALENTEMENTE AL GRUPO DE AUTO ROTURA; EN DONDE EL GRUPO DE AUTO ROTURA ESTA UNIDO A DICHO AGENTE MEDICINAL A TRAVES DE UN ENLACE DE AMIDA ENTRE B Y UNA AMIDA DEL AGENTE MEDICINAL; (III) UN POLIMERO DE DEPOSITO TAL COMO POLIETILENGLICOL QUE TIENE UN PESO MOLECULAR ENTRE 40.000 A 80.000 QUE ESTA UNIDO A LA CADENA LATERAL A O B A TRAVES DE UNA UNION A UN GRUPO ACILO O GRUPO ALQUILO C16-C18. EL GRUPO DIPEPTIDO COMPRENDE LA ESTRURA DE FORMULA (i) DONDE: R1, R2, R4 Y R8 SE SELECCIONAN INDEPENDIENTEMENTE DE H, ALQUILO C1-C18, ALQUENILO C2-C18, (ALQUILO C1-C18)OH, (ALQUILO C1-C18)SH, ENTRE OTROS; R3 ES ALQUILO C1-C18, (ALQUILO C1-C18)NH2, (ALQUILO C0-C4)CICLOALQUILO C3-C6, (ALQUILO C0-C4)(HETEROCICLICO C2-C5), ENTRE OTROS. DICHO COMPLEJO MEJORA LA SOLUBILIDAD, ESTABILIDAD Y/O FARMACOCINETICA DEL PROFARMACO
PE2011001237A 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido PE20120331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13922708P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
PE20120331A1 true PE20120331A1 (es) 2012-04-14

Family

ID=42316744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001237A PE20120331A1 (es) 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido

Country Status (13)

Country Link
US (1) US20110237493A1 (es)
EP (1) EP2376098A4 (es)
JP (2) JP2012512898A (es)
KR (1) KR20110114568A (es)
CN (1) CN102300580A (es)
AU (1) AU2009335711A1 (es)
CA (1) CA2747195A1 (es)
IL (1) IL213341A0 (es)
MX (1) MX2011006527A (es)
PE (1) PE20120331A1 (es)
RU (1) RU2578591C2 (es)
SG (1) SG172290A1 (es)
WO (1) WO2010080605A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
CA2674354A1 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
EP2676673B1 (en) 2008-06-17 2016-11-16 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
CA2727161A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
AU2009335712B2 (en) 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
MX2011006524A (es) 2008-12-19 2011-08-17 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
CA2788304A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
RU2013102991A (ru) * 2010-06-24 2014-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Связанные с дипептидом лекарственные средства
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
ES2713952T3 (es) 2010-12-22 2019-05-24 Univ Indiana Res & Tech Corp Análogos de glucagón que muestran actividad de receptor de GIP
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
HRP20170890T1 (hr) 2011-06-22 2017-09-08 Indiana University Research And Technology Corporation Suagonisti glukagonskog/glp-1 receptora
WO2013074910A1 (en) * 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP2793932B1 (en) 2011-12-20 2018-10-03 Indiana University Research and Technology Corporation Ctp-based insulin analogs for treatment of diabetes
CN103172726B (zh) * 2011-12-22 2017-06-13 杭州淳泰科技有限公司 胰泌素类似物及其制备方法和用途
EP2820038B1 (en) 2012-03-01 2020-06-17 Novo Nordisk A/S Glp-1 prodrugs
WO2013192129A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
SMT202200173T1 (it) 2016-06-01 2022-05-12 Athira Pharma Inc Composti
IL298338A (en) * 2020-05-26 2023-01-01 Univ Indiana Res & Tech Corp Pth analogs for the treatment of hypoparathyroidism
CN116157143A (zh) 2020-07-22 2023-05-23 诺和诺德股份有限公司 适合于口服递送的glp-1和gip受体的共激动剂
KR20230104118A (ko) 2020-11-06 2023-07-07 노보 노르디스크 에이/에스 Glp-1 전구약물 및 이의 용도
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
AR129270A1 (es) 2022-05-10 2024-08-07 Novo Nordisk As Profármacos y usos de los mismos
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740385A (en) * 1970-05-07 1973-06-19 M Ondetti N-terminal derivatives of secretin
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
US4741897A (en) * 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
WO2000058360A2 (en) * 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
AUPQ661800A0 (en) * 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
AU2001284697A1 (en) * 2000-08-04 2002-02-18 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
EP1324779B1 (en) * 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2002086075A2 (en) * 2001-04-19 2002-10-31 The Scripps Research Institute Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7238656B2 (en) * 2001-08-29 2007-07-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
JP2005519041A (ja) * 2001-12-20 2005-06-30 イーライ・リリー・アンド・カンパニー 長期作用を備えたインスリン分子
FR2842209B1 (fr) * 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
KR100733940B1 (ko) * 2003-03-19 2007-06-29 일라이 릴리 앤드 캄파니 폴리에틸렌 글리콜이 연결된 ｇｌｐ-1 화합물
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
EP2932981B1 (en) * 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
WO2005035003A2 (en) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US20070099841A1 (en) * 2005-09-08 2007-05-03 New River Pharmaceuticals Inc. Prodrugs of T3 and T4 with enhanced bioavailability
CA2646598C (en) * 2006-03-21 2014-08-19 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
JP5840345B2 (ja) * 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
BRPI0807728A2 (pt) * 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
EP2249853A4 (en) * 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
MX2011006524A (es) * 2008-12-19 2011-08-17 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.

Also Published As

Publication number Publication date
SG172290A1 (en) 2011-07-28
CA2747195A1 (en) 2010-07-15
JP2012512898A (ja) 2012-06-07
KR20110114568A (ko) 2011-10-19
CN102300580A (zh) 2011-12-28
WO2010080605A1 (en) 2010-07-15
EP2376098A1 (en) 2011-10-19
JP2016028082A (ja) 2016-02-25
RU2011129764A (ru) 2013-01-27
US20110237493A1 (en) 2011-09-29
AU2009335711A1 (en) 2010-07-15
MX2011006527A (es) 2011-08-17
IL213341A0 (en) 2011-07-31
EP2376098A4 (en) 2014-06-11
RU2578591C2 (ru) 2016-03-27

Similar Documents

Publication Publication Date Title
PE20120331A1 (es) Agentes medicinales unidos a dipeptido
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20091575A1 (es) Derivados bifenilo como inhibidores del virus de la hepatitis c
PE20150041A1 (es) Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
AR078151A1 (es) Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas.
ECSP099638A (es) Nuevo compuesto de adenina
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
ES2567418T3 (es) Derivados citotóxicos de benzodiazepina
PH12012500519A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20070171A1 (es) GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
SV2008002969A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
DOP2010000046A (es) Compuestos de biciclolactama sustituida
PE20090226A1 (es) PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
PE20081834A1 (es) Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
PE20120533A1 (es) Inhibidores del virus de la hepatitis c
PA8759501A1 (es) Formas cristalinas
MX2018005737A (es) Composiciones de profarmaco de alta penetracion de peptidos y compuestos relacionados con peptidos.
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FC Refusal